Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83,064 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness of S-1-Based Chemoradiotherapy in Patients 70 Years and Older With Esophageal Squamous Cell Carcinoma: A Randomized Clinical Trial.
Wang X, Han W, Zhang W, Wang X, Ge X, Lin Y, Zhou H, Hu M, Wang W, Liu K, Lu J, Qie S, Zhang J, Deng W, Wang L, Han C, Li M, Zhang K, Li L, Wang Q, Shi H, Yu Z, Zhao Y, Sun X, Shi Y, Pang Q, Zhou Z, Liang J, Chen D, Feng Q, Bi N, Zhang T, Deng L, Wang W, Liu W, Wang J, Zhai Y, Wang J, Chen W, Chen J, Xiao Z; Jing-Jin-Ji Esophageal and Esophagogastric Cancer Radiotherapy Oncology Group (3JECROG). Wang X, et al. Among authors: wang w, wang l, wang j, wang q. JAMA Netw Open. 2023 May 1;6(5):e2312625. doi: 10.1001/jamanetworkopen.2023.12625. JAMA Netw Open. 2023. PMID: 37195667 Free PMC article. Clinical Trial.
Applying post-neoadjuvant pathologic stage as prognostic tool in esophageal squamous cell carcinoma.
Han W, Deng W, Wang Q, Ni W, Li C, Zhou Z, Liang J, Chen D, Feng Q, Bi N, Zhang T, Wang X, Deng L, Wang W, Liu W, Wang J, Xue Q, Mao Y, Liu X, Fang D, Li J, Wang D, Zhao J, Xiao Z. Han W, et al. Among authors: wang x, wang w, wang j, wang d, wang q. Front Oncol. 2022 Nov 10;12:998238. doi: 10.3389/fonc.2022.998238. eCollection 2022. Front Oncol. 2022. PMID: 36439431 Free PMC article.
Efficacy and safety of definitive chemoradiotherapy with or without induction immune checkpoint inhibitors in patients with stage III non-small cell lung cancer.
Yang Y, Wang J, Zhang T, Zhou Z, Wang Y, Jiang Y, Liu W, Xiao Z, Deng L, Feng Q, Wang X, Lv J, Wang W, Xue Q, Wang J, Li YX, Bi N. Yang Y, et al. Among authors: wang x, wang w, wang j, wang y. Front Immunol. 2023 Nov 24;14:1281888. doi: 10.3389/fimmu.2023.1281888. eCollection 2023. Front Immunol. 2023. PMID: 38077319 Free PMC article.
Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study).
Wang Y, Deng L, Wang J, Zhang T, Wang W, Wang X, Liu W, Wu Y, Lv J, Feng Q, Zhou Z, Wang J, Wang L, Wang Z, Bi N. Wang Y, et al. Among authors: wang x, wang w, wang l, wang j, wang z. Front Immunol. 2024 Jan 15;14:1341584. doi: 10.3389/fimmu.2023.1341584. eCollection 2023. Front Immunol. 2024. PMID: 38288117 Free PMC article.
83,064 results
You have reached the last available page of results. Please see the User Guide for more information.